Shadi Ziaie - Department of Clinical Pharmacy, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran- Department of Nephrology and Kidney Transplantation, Shahid Labbafnejad Medical Center, Shahid Beheshti University of Medical Sciences,Tehr
Mehran Koucheck - Critical Care Medicine Ward, Anesthesiology Department, Imam Hossein (A.S.) Medical and Educational Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
MirMohammad Miri - Critical Care Medicine Ward, Anesthesiology Department, Imam Hossein (A.S.) Medical and Educational Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Sara Salarian - Critical Care Medicine Ward, Anesthesiology Department, Imam Hossein (A.S.) Medical and Educational Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Seyedpouzhin Shojaei - Critical Care Medicine Ward, Anesthesiology Department, Imam Hossein (A.S.) Medical and Educational Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Mehrdad Haghighi - Department of Infectious Disease, Imam Hossein (A.S.) Medical and Educational Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

In late December ۲۰۱۹, a cluster of unexplained pneumonia cases has been reported in Wuhan, China, named coronavirus disease ۲۰۱۹ (COVID -۱۹) which has been spreading in ۲۰۴ countries. To date no pharmaceutical products have been approved for the treatment of this viral pneumonia. Based on rapid spread of the disease and high disease burden, several agents have been proposed for treatment of this viral pneumonia, mainly antivirals and immunomodulator agents and underwent in-vitro, animal and clinical trials. Some of these agents have been revealed promising preclinical results but, non of them approved yet. This review aims to summarize the current knowledge about the mechanism and considerations of widely used investigational agents that are used in the treatment of COVID-۱۹ as off-label.

COVID-۱۹, Pneumonia, Antiviral, Immunomodulator, Interferon, IVIG, Tocilizumab, Remdesivir